You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

~ Buy the TACLONEX (betamethasone dipropionate; calcipotriene) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR TACLONEX

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Taclonex

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00437255 ↗	Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis	Completed	Galderma Laboratories, L.P.	Phase 4	2006-08-01	Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
NCT00608777 ↗	Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)	Terminated	Genentech, Inc.	Phase 4	2008-01-01	The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe plaque psoriasis. It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB and thus allow patients to continue efalizumab without interruption.
NCT00608777 ↗	Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)	Terminated	Derm Research, PLLC	Phase 4	2008-01-01	The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe plaque psoriasis. It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB and thus allow patients to continue efalizumab without interruption.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Taclonex

Condition Name

Chart
Table

Condition Name for Taclonex
Intervention	Trials
Plaque Psoriasis	5
Scalp Psoriasis	5
Psoriasis Vulgaris	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Taclonex
Intervention	Trials
Psoriasis	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Taclonex

Trials by Country

Map
Table

Trials by Country for Taclonex
Location	Trials
United States	51
Canada	9
United Kingdom	7
France	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Taclonex
Location	Trials
California	5
Texas	5
North Carolina	4
Florida	4
Indiana	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Taclonex

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Taclonex
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	1
Phase 2	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Taclonex
Clinical Trial Phase	Trials
Completed	11
Terminated	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Taclonex

Sponsor Name

Chart
Table

Sponsor Name for Taclonex
Sponsor	Trials
LEO Pharma	6
Genentech, Inc.	1
Taro Pharmaceuticals USA	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Taclonex
Sponsor	Trials
Industry	14
Other	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.